CURX logo

Curanex Pharmaceuticals Inc

CURX

Build a strategy around CURX

Accountable AI Logo

Curanex Pharmaceuticals Inc AI Insights

Informational only. Not investment advice.
As of 2025-12-24

Snapshot

  • Zero revenue pre-clinical biotech burning 9.7M TTM cash with 5.8M remaining - under 8 months runway at current rate[Cash and Equivalents]
  • Trading at 0.72x book value (14.3M equity vs 10.2M market cap) - market pricing significant dilution or failure risk[P/B Ratio]
  • R&D spend of 677K is just 56% of opex - unusually low for biotech, G&A of 274K suggests lean operations[Research and Development]

Watch Triggers

  • Cash and Equivalents: Falls below 3M or new equity filingSignals imminent dilution event - watch for S-3 or ATM filings
  • Research and Development: Increases >50% QoQWould indicate pipeline advancement but accelerate cash burn timeline
  • Total Revenue TTM: Any revenue recognitionPartnership or licensing deal would transform thesis entirely

Bull Case

Clean balance sheet with 0.004 debt/equity and 14.2M working capital provides flexibility for strategic pivots or partnerships

Debt to EquityWorking Capital

Sub-book valuation (0.72x) means successful pipeline news could drive 40%+ upside to tangible book alone

P/B RatioTangible Book Value

Bear Case

Cash runway under 8 months at current burn guarantees near-term dilution; 15.7M recent raise already depleted to 5.8M

Free Cash Flow TTMCash and Equivalents

ROE of -17.4% and ROA of -17.2% with zero revenue - pure cash burn with no visibility to inflection

ROE TTMROA TTM

Bull vs Bear Balance

AI-generated sentiment analysis based on fundamental metrics and market conditions.

BearBull
25%

Leverage CURX's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.

Take Me to The Editor

Forward Thesis

Equity raise required within 6-9 months to fund operations, likely 30-50% dilution

3-12mhigh
  • Cash burn of 9.7M TTM vs 5.8M cash
  • Zero revenue, no near-term path to profitability
  • Recent 15.7M capital raise already consumed
FCF TTM: -9.7MCash: 5.8M (up from 109K via raise)Shares outstanding: 25.6M

Valuation Context

Caveats

Public Strategies Rankings

See how Curanex Pharmaceuticals Inc ranks across different investment strategies.

Leverage CURX's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.

Data Partners
Morningstar Logo

Fundamental company data provided by Morningstar, updated daily.

Accountable Finance, Inc. Disclaimer
accountable.finance is not operated by a broker or a dealer. Under no circumstances does any information posted on accountable.finance represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. In no event shall accountable.finance be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on accountable.finance, or relating to the use of, or inability to use, accountable.finance or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. Stock quotes and fundamental company data provided by Morningstar, updated daily.

Accountable Logo
© 2026 Accountable Finance, Inc. All rights reserved.